Literature DB >> 23791963

AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications.

Xinping Huang1, Antja-Voy Hartley, Yishi Yin, Jeremy H Herskowitz, James J Lah, Kerry J Ressler.   

Abstract

The adeno-associated virus (AAV) is one of the most useful viral vectors for gene delivery for both in vivo and in vitro applications. A variety of methods have been established to produce and characterize recombinant AAV (rAAV) vectors; however most methods are quite cumbersome and obtaining consistently high titer can be problematic. This protocol describes a triple-plasmid co-transfection approach with 25 kDa linear polyethylenimine (PEI) in 293 T cells for the production of AAV serotype 2. Seventy-two hours post-transfection, supernatant and cells were harvested and purified by a discontinuous iodixanol density gradient ultracentrifugation, then dialyzed and concentrated with an Amicon 15 100,000 MWCO concentration unit. To optimize the protocol for AAV2 production using PEI, various N/P ratios and DNA amounts were compared. We found that an N/P ratio of 40 coupled with 1.05 μg DNA per ml of media (21 μg DNA/15 cm dish) was found to produce the highest yields for viral replication and assembly measured multiple ways. The infectious units, as determined by serial dilution, were between 1×10(8) and 2×10(9) IU/ml. The genomic titer of the viral stock was determined by qPCR and ranged from 2×10(12) to 6×10(13) VG/ml. These viral vectors showed high expression both in vivo within the brain and in vitro in cell culture. The use of linear 25 kDa polyethylenamine PEI as a transfection reagent is a simple, more cost-effective, and stable means of high-throughput production of high-titer AAV serotype 2. The use of PEI also eliminates the need to change cell medium post-transfection, lowering cost and workload, while producing high-titer, efficacious AAV2 vectors for routine gene transfer.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AAV; AAV2-GFP; N/P ratio; Optimization; Polyethylenimine (PEI); Recombinant virus

Mesh:

Substances:

Year:  2013        PMID: 23791963      PMCID: PMC3775943          DOI: 10.1016/j.jviromet.2013.06.008

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  31 in total

1.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

Authors:  Glenn P Niemeyer; Roland W Herzog; Jane Mount; Valder R Arruda; D Michael Tillson; John Hathcock; Frederik W van Ginkel; Katherine A High; Clinton D Lothrop
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

2.  Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors.

Authors:  Sharon E Reed; Elizabeth M Staley; John P Mayginnes; David J Pintel; Gregory E Tullis
Journal:  J Virol Methods       Date:  2006-09-06       Impact factor: 2.014

3.  Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale.

Authors:  Martin Lock; Mauricio Alvira; Luk H Vandenberghe; Arabinda Samanta; Jaan Toelen; Zeger Debyser; James M Wilson
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

4.  High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency.

Authors:  E Ayuso; F Mingozzi; J Montane; X Leon; X M Anguela; V Haurigot; S A Edmonson; L Africa; S Zhou; K A High; F Bosch; J F Wright
Journal:  Gene Ther       Date:  2009-12-03       Impact factor: 5.250

5.  AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice.

Authors:  Tomomi Kiyota; Masaru Yamamoto; Bryce Schroder; Michael T Jacobsen; Russell J Swan; Mary P Lambert; William L Klein; Howard E Gendelman; Richard M Ransohoff; Tsuneya Ikezu
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

6.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

7.  Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells.

Authors:  Yves Durocher; Phuong Lan Pham; Gilles St-Laurent; Danielle Jacob; Brian Cass; Parminder Chahal; Cara J Lau; Joséphine Nalbantoglu; Amine Kamen
Journal:  J Virol Methods       Date:  2007-04-30       Impact factor: 2.014

Review 8.  Transient transfection methods for clinical adeno-associated viral vector production.

Authors:  J Fraser Wright
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

9.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Authors:  Michael G Kaplitt; Andrew Feigin; Chengke Tang; Helen L Fitzsimons; Paul Mattis; Patricia A Lawlor; Ross J Bland; Deborah Young; Kristin Strybing; David Eidelberg; Matthew J During
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

10.  Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo.

Authors:  Mini Thomas; Qing Ge; James J Lu; Jianzhu Chen; Alexander M Klibanov
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

View more
  17 in total

1.  AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma.

Authors:  Darrick L Yu; Ashley A Stegelmeier; Byram W Bridle; James J Petrik; Sarah K Wootton; Natalie Chow; Amira D Rghei; Kathy Matuszewska; Jack Lawler
Journal:  Cancer Gene Ther       Date:  2019-06-04       Impact factor: 5.987

2.  VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease.

Authors:  Fu-Lei Tang; Joanna R Erion; Yun Tian; Wei Liu; Dong-Min Yin; Jian Ye; Baisha Tang; Lin Mei; Wen-Cheng Xiong
Journal:  J Neurosci       Date:  2015-07-22       Impact factor: 6.167

3.  Neuro-mesenchymal units control ILC2 and obesity via a brain-adipose circuit.

Authors:  Filipa Cardoso; Roel G J Klein Wolterink; Cristina Godinho-Silva; Rita G Domingues; Hélder Ribeiro; Joaquim Alves da Silva; Inês Mahú; Ana I Domingos; Henrique Veiga-Fernandes
Journal:  Nature       Date:  2021-08-18       Impact factor: 69.504

4.  AIBP protects against metabolic abnormalities and atherosclerosis.

Authors:  Dina A Schneider; Soo-Ho Choi; Colin Agatisa-Boyle; Laurence Zhu; Jungsu Kim; Jennifer Pattison; Dorothy D Sears; Philip L S M Gordts; Longhou Fang; Yury I Miller
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

5.  AAV6 K531 serves a dual function in selective receptor and antibody ADK6 recognition.

Authors:  Antonette D Bennett; Kristine Wong; Jordyn Lewis; Yu-Shan Tseng; J Kennon Smith; Paul Chipman; Robert McKenna; R Jude Samulski; Jürgen Kleinschmidt; Mavis Agbandje-McKenna
Journal:  Virology       Date:  2018-03-30       Impact factor: 3.616

6.  Rapid initiation of cell cycle reentry processes protects neurons from amyloid-β toxicity.

Authors:  Stefania Ippati; Yuanyuan Deng; Julia van der Hoven; Celine Heu; Annika van Hummel; Sook Wern Chua; Esmeralda Paric; Gabriella Chan; Astrid Feiten; Thomas Fath; Yazi D Ke; Nikolas K Haass; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 12.779

Review 7.  Molecular design for recombinant adeno-associated virus (rAAV) vector production.

Authors:  Juan Jose Aponte-Ubillus; Daniel Barajas; Joseph Peltier; Cameron Bardliving; Parviz Shamlou; Daniel Gold
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-04       Impact factor: 4.813

8.  Thermal Stability as a Determinant of AAV Serotype Identity.

Authors:  Antonette Bennett; Saajan Patel; Mario Mietzsch; Ariana Jose; Bridget Lins-Austin; Jennifer C Yu; Brian Bothner; Robert McKenna; Mavis Agbandje-McKenna
Journal:  Mol Ther Methods Clin Dev       Date:  2017-07-24       Impact factor: 6.698

Review 9.  Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties.

Authors:  Weihong Qu; Mingxi Wang; Yaqing Wu; Ruian Xu
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

10.  A role for Tac2, NkB, and Nk3 receptor in normal and dysregulated fear memory consolidation.

Authors:  Raül Andero; Brian G Dias; Kerry J Ressler
Journal:  Neuron       Date:  2014-06-26       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.